MEDGENERA | NIH to Decide the Fate of Revolutionary Gene Editing Technology

National Institutes of Health (NIH)’s Recombinant DNA Advisory Committee (RAC) will review the decision of using the CRISPR/Cas9 technology for the first-in-human use for gene editing.
Like what you read? Give a round of applause.

From a quick cheer to a standing ovation, clap to show how much you enjoyed this story.